6/21/2023 0 Comments Step seq ipaThe sequence listing provided must be in an electronic form and accompanied by a statement to the effect that does not include matter which goes beyond the disclosure in the international application as filed. Where the application does not contain a separate sequence listing in XML format examiners should request a sequence listing under Rule 13ter.1(a). Where the provided XML sequence listing does not comply with WIPO ST.26 standard the applicant is to be advised via a comment in Box VII of PCT/ISA/237, Examiners are to then to establish the opinion to the extent that a meaningful search could be carried out without a WIPO ST.26 compliant listing. A copy of the validation report produced by the WIPO sequence tool is then placed on file for dispatch to the applicant by the PCT unit. The sequence listing is inputted into the WIPO sequence validation tool which then validates whether the sequence is in the required format. The relevant examination section will then determine, if the provided XML sequence listing complies with WIPO ST.26. ![]() The standard requires the listing to be provided in XML format.Īfter initial processing of the application by PCT unit, it will be forwarded along with the attached sequence listing to the relevant examination section. Where the international application contains a disclosure of a nucleotide and/or amino acid sequence, it must be accompanied by sequence listing that is compliant with WIPO ST.26 Standard. The following information relates to PCT applications filed on or after 1 July 2022 If however the sequence listing is only filed in response to a Rule 13ter request by the ISA then the sequence listing does not form part of the description (unless the subject of an Article 34 amendment) and will not be part of the pamphlet ( Rule 13ter.1(f)).Įxaminers should note that the expressions "nucleotide sequence" and "amino acid sequence" are defined to mean an unbranched sequence of ten or more contiguous nucleotides and an unbranched sequence of four or more contiguous amino acids, respectively branched sequences are specifically excluded ( Annex C). ![]() Where the sequence listing was originally filed as part of the description or where it was filed in response to an Article 14 objection (certain defects in the specification) by the Receiving Office, the sequence listing forms part of the description ( Rule 5.2) and hence forms part of the pamphlet. The listing may be filed as part of the specification or it can be furnished separately at a later date.
0 Comments
Leave a Reply. |